Company intelligence / Profile preview
Pharmexa-Epimmune
San Diego, California, USApmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Employees
- ~27
- Development stage
- Phase 3
01
Overview
Pharmexa-Epimmune was a biotechnology company focused on developing peptide and recombinant protein-based vaccines for cancer, chronic, and infectious diseases. The company had multiple clinical candidates spanning preclinical through late-stage development prior to its discontinuation and sale in April 2009.
- Therapeutic areas
- OncologyInfectious DiseasesOther
- Modalities
- Peptide-based vaccinesRecombinant protein vaccinesPolypeptide-based technologies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
National Cancer Research Institute (NCRI), UKNational Institutes of Health (NIH), USLicense partners included H. Lundbeck, Bavarian Nordic, GENimmune.
Beyond the preview
Go deeper on Pharmexa-Epimmune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pharmexa-Epimmune.